文献速递胸部肿瘤

二甲双胍增强顺铂诱导的凋亡并预防KRAS/LKB1共突变NSCLC顺铂耐药

Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC.
PubMed 文献 · J Thorac Oncol · 2018-08-24

研究假设KRAS激活突变与LKB1失活协同促进NSCLC侵袭性,且KRAS/LKB1共突变肿瘤对代谢应激(如二甲双胍)更敏感。回顾性分析TAILOR试验患者标本,并在细胞和PDX模型中测试二甲双胍。结果显示KRAS/LKB1共突变患者总生存有更差趋势(HR 2.02,95%CI 0.94-4.35,p=0.072);二甲双胍在共突变PDX中增强顺铂活性并预防耐药(联合应答率75% vs 顺铂0%),减少CD133+细胞。

要点

  • KRAS/LKB1共突变NSCLC患者总生存有更差趋势,HR 2.02(95%CI 0.94-4.35,p=0.072)。
  • 二甲双胍在KRAS/LKB1共突变PDX中增强顺铂疗效并减少CD133+细胞。
  • 二甲双胍联合顺铂预防耐药:应答率75%,顺铂单药0%。

核心结论

  • LKB1突变尤其合并KRAS突变可能定义一种更具侵袭性的NSCLC亚型。
  • 二甲双胍与顺铂协同对抗KRAS/LKB1共突变肿瘤,并可能通过靶向CD133+肿瘤干细胞预防或延迟顺铂耐药。

研究设计与样本

  • 回顾性分析TAILOR试验入组NSCLC患者组织标本中KRAS/LKB1共突变的频率和预后价值。
  • 构建LKB1敲低和LKB1过表达的稳定同源H1299和A549细胞变体,用于体外测试二甲双胍疗效。
  • 在NSCLC患者来源异种移植(PDX)中研究二甲双胍对顺铂耐药CD133+细胞的作用。

主要发现

  • KRAS/LKB1共突变患者较KRAS突变患者总生存有更差趋势(HR 2.02,95%CI 0.94-4.35,p=0.072)。
  • 临床前实验中,二甲双胍产生促凋亡效应,并特异性地在KRAS/LKB1共突变PDX中增强顺铂抗癌活性。
  • 二甲双胍预防连续5个周期顺铂治疗后的获得性耐药(二甲双胍+顺铂应答率75%,顺铂应答率0%),同时减少CD133+细胞。

关键数值与推荐

  • KRAS/LKB1共突变患者总生存风险比HR 2.02(95%CI 0.94-4.35,p=0.072)。
  • 连续5个周期顺铂治疗:二甲双胍+顺铂应答率75%,顺铂单药应答率0%。

临床怎么用

  • KRAS/LKB1共突变NSCLC可能为更具侵袭性亚型,需关注预后。
  • 二甲双胍联合铂类化疗可能用于KRAS/LKB1共突变NSCLC,以增强疗效并预防耐药。

局限性

  • 预后分析为回顾性研究,样本来自TAILOR试验,共突变与生存关联仅为趋势(p=0.072)。
  • 临床前结果来自细胞和PDX模型,需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We hypothesized that activating KRAS mutations and inactivation of the liver kinase B1 (LKB1) oncosuppressor can cooperate to sustain NSCLC aggressiveness. We also hypothesized that the growth advantage of KRAS/LKB1 co-mutated tumors could be balanced by higher sensitivity to metabolic stress conditions, such as metformin treatment, thus revealing new strategies to target this aggressive NSCLC subtype. METHODS: We retrospectively determined the frequency and prognostic value of KRAS/LKB1 co-mutations in tissue specimens from NSCLC patients enrolled in the TAILOR trial. We generated stable LKB1 knockdown and LKB1-overexpressing isogenic H1299 and A549 cell variants, respectively, to test the in vitro efficacy of metformin. We also investigated the effect of metformin on cisplatin-resistant CD133+ cells in NSCLC patient-derived xenografts. RESULTS: We found a trend towards worse overall survival in patients with KRAS/LKB1 co-mutated tumors as compared to KRAS-mutated ones (hazard ratio: 2.02, 95% confidence interval: 0.94-4.35, p = 0.072). In preclinical experiments, metformin produced pro-apoptotic effects and enhanced cisplatin anticancer activity specifically in KRAS/LKB1 co-mutated patient-derived xenografts. Moreover, metformin prevented the development of acquired tumor resistance to 5 consecutive cycles of cisplatin treatment (75% response rate with metformin-cisplatin as compared to 0% response rate with cisplatin), while reducing CD133+ cells. CONCLUSIONS: LKB1 mutations, especially when combined with KRAS mutations, may define a specific and more aggressive NSCLC subtype. Metformin synergizes with cisplatin against KRAS/LKB1 co-mutated tumors, and may prevent or delay the onset of resistance to cisplatin by targeting CD133+ cancer stem cells. This study lays the foundations for combining metformin with standard platinum-based chemotherapy in the treatment of KRAS/LKB1 co-mutated NSCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Moro M, Caiola E, Ganzinelli M, et al. Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC. J Thorac Oncol. 2018. PMID: 30149143. doi:10.1016/j.jtho.2018.07.102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。